Other · developed by Nasus Pharma
FMXIN002 (NS002) is a nasal powder spray of epinephrine microspheres, given as a single dose in one nostril. It is studied in allergy and anaphylaxis, including after a nasal allergen challenge.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07228325 | Phase 1/2 | Anaphylaxis | Enrolling by invitation | NSRX |
| NCT06205134 | Phase 1/2 | Anaphylaxis | Completed | NSRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AllergyAnaphylactic ReactionAnaphylaxis
Updated Oct 25, 2026. Something wrong or missing? Report it on the NSRX page.
See NSRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NSRX catalysts and pipeline →